NCT02939651View on ClinicalTrials.gov

A Study of Pembrolizumab in Patients With Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

October 26, 2016

Primary Completion Date

February 28, 2018

Study Completion Date

March 31, 2020

Conditions
Neuroendocrine Tumors
Interventions
DRUG

Pembrolizumab

Pembrolizumab given intravenously at a fixed dose of 200mg every 3 weeks

Trial Locations (2)

19111

Fox Chase Cancer Center, Philadelphia

Unknown

MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Fox Chase Cancer Center

OTHER

NCT02939651 - A Study of Pembrolizumab in Patients With Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter